State of Wisconsin Investment Board increased its position in Bausch Health Companies Inc (NYSE:BHC) by 80.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 399,620 shares of the company’s stock after buying an additional 177,764 shares during the quarter. State of Wisconsin Investment Board’s holdings in Bausch Health Companies were worth $9,862,000 at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Bessemer Group Inc. purchased a new stake in shares of Bausch Health Companies during the fourth quarter valued at $33,000. Beutel Goodman & Co Ltd. purchased a new stake in shares of Bausch Health Companies during the first quarter valued at $38,000. Lindbrook Capital LLC purchased a new stake in shares of Bausch Health Companies during the fourth quarter valued at $41,000. Providence Capital Advisors LLC purchased a new stake in shares of Bausch Health Companies during the first quarter valued at $49,000. Finally, Winslow Evans & Crocker Inc. lifted its holdings in shares of Bausch Health Companies by 43.5% during the first quarter. Winslow Evans & Crocker Inc. now owns 3,300 shares of the company’s stock valued at $82,000 after purchasing an additional 1,000 shares during the last quarter. Institutional investors and hedge funds own 53.67% of the company’s stock.
Several equities research analysts have recently commented on BHC shares. Zacks Investment Research downgraded Bausch Health Companies from a “buy” rating to a “hold” rating in a report on Friday, February 15th. Wells Fargo & Co upped their target price on Bausch Health Companies from $9.00 to $25.19 and gave the company an “underperform” rating in a report on Tuesday, February 19th. HC Wainwright reaffirmed a “buy” rating on shares of Bausch Health Companies in a report on Thursday, February 28th. Mizuho increased their price objective on Bausch Health Companies from $39.00 to $41.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Finally, SunTrust Banks began coverage on Bausch Health Companies in a research note on Tuesday, March 19th. They issued a “buy” rating and a $30.00 price objective for the company. Three research analysts have rated the stock with a sell rating, four have given a hold rating and ten have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $27.65.
Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Monday, May 6th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.14. The firm had revenue of $2.02 billion during the quarter, compared to the consensus estimate of $2.03 billion. Bausch Health Companies had a positive return on equity of 47.01% and a negative net margin of 19.27%. The business’s revenue for the quarter was up 1.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.89 EPS. On average, research analysts forecast that Bausch Health Companies Inc will post 4.15 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Bausch Health Companies Inc (NYSE:BHC) Shares Bought by State of Wisconsin Investment Board” was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.com-unik.info/2019/06/15/bausch-health-companies-inc-nysebhc-shares-bought-by-state-of-wisconsin-investment-board.html.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Read More: Trading on Margin
Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.